GIT2 and pilocytic astrocytoma: GIT2::BRAF and GIT2::PDGFRB fusions were described in pilocytic astrocytoma [8] and chronic myeloproliferative disorders [12], respectively, with breakpoints in exon 12 of GIT2. Altered protein–protein interactions related to ankyrin and ARF-GAP domains of GIT2 are the presumed mechanism of oncogene activation [12].